Article
Immunology
M. Stanojevic, M. Grant, S. K. Vesely, S. Knoblach, C. G. Kanakry, J. Nazarian, E. Panditharatna, K. Panchapakesan, R. E. Gress, J. Holter-Chakrabarty, Kirsten M. M. Williams
Summary: A new method for blood MRD monitoring of leukemia after HCT was developed using ddPCR, which showed promising results in detecting minimal residual disease earlier in patients with active acute leukemia. The TAA/ABL1 ratio has the potential to serve as a novel surrogate biomarker for relapse of acute leukemia after HCT.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Cristina Tecchio, Anna Russignan, Mauro Krampera
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) benefits adult ALL patients, but those with MRD may require interventions with side effects. The significance of MFC in ALL treatment is widely recognized, but there is limited data on MRD monitoring in allo-HSCT settings. This article aims to summarize and discuss the role of MFC detection of MRD in adult ALL patients undergoing allo-HSCT, including sensitivity, timing, and relation to other MRD assessment techniques.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Giovanni Manfredi Assanto, Ilaria Del Giudice, Irene Della Starza, Roberta Soscia, Marzia Cavalli, Mattia Cola, Vittorio Bellomarino, Mariangela Di Trani, Anna Guarini, Robin Foa
Summary: Minimal/measurable residual disease (MRD) monitoring is changing the management of hematologic malignancies by providing refined risk stratification and treatment decision making. ddPCR, as a third-generation PCR technique, has the advantages of direct, accurate detection and quantification of low-abundance nucleic acids. However, its broad application in clinical practice is limited due to the lack of international guidelines.
FRONTIERS IN ONCOLOGY
(2023)
Review
Immunology
Justin Loke, Richard Buka, Charles Craddock
Summary: While most AML patients achieve complete remission with intensive chemotherapy, many face a risk of relapse if treated with chemotherapy alone. Allogeneic stem cell transplant has become a key treatment strategy for AML patients, especially for those in first complete remission and advanced stages. Despite a decrease in transplant-related mortality, there remains a need to address the risk of disease relapse.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Sami B. Kanaan, Francesca Urselli, Jerald P. Radich, J. Lee Nelson
Summary: By using a highly sensitive chimerism assay, this study demonstrates the ability to predict the risk of relapse in leukemia patients after allogeneic hematopoietic cell transplant. Compared to traditional measurement methods, this assay provides more accurate detection of recipient cells and, when combined with flow cytometry, improves the prediction of relapse risk. This technology is important for early intervention.
Article
Immunology
Shuang Fan, Tian-Zhong Pan, Li-Ping Dou, Yan-Min Zhao, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Xiao-Jun Huang, Xiao-Dong Mo
Summary: The study aimed to assess the efficacy of preemptive interferon-alpha (IFN-alpha) treatment in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a real-world setting. The results showed that preemptive IFN-alpha treatment can eliminate measurable residual disease (MRD) in AML patients and improve leukemia-free survival.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Miguel Waterhouse, Sandra Pennisi, Dietmar Pfeifer, Florian Scherer, Robert Zeiser, Justus Duyster, Hartmut Bertz, Juergen Finke, Jesus Duque-Afonso
Summary: This study demonstrates the clinical utility of monitoring measurable residual disease (MRD) and mixed chimerism (MC) in circulating cell-free DNA (cfDNA) for early relapse detection in patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study finds that MC in cfDNA at an optimal threshold of 18% can discriminate between patients with hematological relapse and those in complete remission after allo-HSCT. The use of a targeted next-generation sequencing (NGS) panel allows for the detection of mutations in cfDNA, which can be used for MRD monitoring.
Article
Oncology
Jong-Mi Lee, Silvia Park, Insik Hwang, Dain Kang, Byung Sik Cho, Hee-Je Kim, Ari Ahn, Myungshin Kim, Yonggoo Kim
Summary: This article presents an ITD-tracing algorithm based on NGS method for monitoring MRD in AML patients. The assay shows high sensitivity and superior performance, and demonstrates prognostic value in AML patients undergoing allogeneic hematopoietic stem cell transplantation.
Article
Hematology
Masatomo Kuno, Satoshi Yamasaki, Nobuharu Fujii, Yasushi Ishida, Takahiro Fukuda, Keisuke Kataoka, Naoyuki Uchida, Yuta Katayama, Maho Sato, Daishi Onai, Toshihiro Miyamoto, Shuichi Ota, Satoshi Yoshioka, Takahide Ara, Akira Hangaishi, Yoshiko Hashii, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshihiro Inamoto
Summary: The study compared myeloid neoplasms (MNs) following allogeneic hematopoietic cell transplantation (HCT) versus autologous HCT using a Japanese HCT registry database. The cumulative incidence of MNs was lower after allogeneic HCT than after autologous HCT, and those following allogeneic HCT developed in younger patients and sooner after HCT. Further research is needed to understand the mechanisms of MN development following allogeneic HCT.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
Sanam Shahid, Nicholas Ceglia, Jean-Benoit Le Luduec, Andrew Mcpherson, Barbara Spitzer, Theodota Kontopoulos, Viktoria Bojilova, M. Kazim Panjwani, Mikhail Roshal, Sohrab P. Shah, Omar Abdel-Wahab, Benjamin Greenbaum, Katharine C. Hsu
Summary: This study investigated the effects of allo-HCT on AML cells using a novel single-cell proteogenomic approach. The results demonstrated immune-related transcriptional signatures in posttransplant relapses, revealing dysfunction in activated natural killer cells and CD8+ T-cell subsets, as well as an expansion of dysfunctional T cells.
Review
Oncology
Li Xuan, Qifa Liu
Summary: Relapse is still the main reason for treatment failure in AML patients undergoing allo-HSCT. Evidence suggests that maintenance therapy post-transplantation, particularly targeted drugs like hypomethylating agents, FLT3 inhibitors, and isocitrate dehydrogenase inhibitors, could benefit AML patients, especially those at high risk.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Oncology
Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel, Nicholas J. Short
Summary: Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML), with different detection platforms having varying sensitivity and applicability. MRD negativity is associated with reduced risk of relapse in AML, but the therapeutic implications remain unclear and require further investigation.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Immunology
Meng-Zhu Shen, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Su Zhao, Ya-Zhen Qin, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Dong Mo
Summary: The long-term efficacy of preemptive interferon-alpha therapy in acute myeloid leukemia patients following allogeneic hematopoietic stem cell transplantation was assessed. The results showed that preemptive interferon-alpha therapy could clear minimal residual disease persistently, prevent relapse, and improve long-term survival in patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Vivian W. K. Li, Rita Yim, Paul Lee, Lynn Chin, Lester Au, Garret M. K. Leung, Joycelyn Sim, Albert K. W. Lie, Eric Tse, Yok-Lam Kwong, Harinder Gill
Summary: Relapse after allogeneic haematopoietic stem cell transplantation is a significant factor in determining the outcome of myelofibrosis patients. This retrospective study of 35 myelofibrosis patients receiving allogeneic HSCT found that 88.6% achieved full donor chimerism within 30 days post-HSCT. The median time to neutrophil and platelet engraftment was 16.8 days and 26 days, respectively. Additionally, relapse after HSCT, high leucocyte count at HSCT, and accelerated/blast phase disease at HSCT were significantly associated with worse overall survival.
ANNALS OF HEMATOLOGY
(2023)
Review
Medicine, General & Internal
Mattia Algeri, Pietro Merli, Franco Locatelli, Daria Pagliara
Summary: Allogeneic hematopoietic stem cell transplantation (HSCT) provides a potentially curative treatment for high-risk or relapsed acute leukemia in children by combining intense preparative radio/chemotherapy with the graft-versus-leukemia (GvL) effect. Advances in donor typing, conditioning regimens, GvHD prophylaxis, and MRD-directed interventions have continuously improved transplant outcomes, expanding the potential application of allotransplantation to most patients. Simultaneously, refinements in chemotherapy protocols and targeted therapies may redefine the indications for HSCT in the future.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Hematology
Vladan Vucinic, Madlen Jentzsch, Sabine Leiblein, Enrica Bach, Yvonne Remane, Kai Schulze-Forster, Michael Cross, Wolfram Poenisch, Sebastian Schwind, Georg-Nikolaus Franke, Uwe Platzbecker, Dietger Niederwieser
Summary: The study found that stem cell mobilization with pegfilgrastim is a feasible and attractive option. Among the 28 related donors examined, 75% had a CD34+ count >50 cells/mu l on day four, and 89% of donors had CD34+ yields >= 4 x 10/kg body weight of the recipient. All grafts were administered without rejections.
Article
Oncology
Natali Pflug, Annika Littauer, David Beverungen, Aleksandra Sretenovic, Linus Wahnschaffe, Till Braun, Annika Dechow, Dennis Jungherz, Moritz Otte, Astrid Monecke, Enrica Bach, Georg-Nikolaus Franke, Sebastian Schwind, Madlen Jentzsch, Uwe Platzbecker, Marco Herling, Vladan Vucinic
Summary: Large granular lymphocyte leukemia (LGLL) is a rare group of diseases that present challenges in diagnosis and treatment. The main challenge lies in distinguishing LGLL from other similar diseases. The variable presentations and phenotypes of T-LGLL and CLPD-NK are often underappreciated. Diagnostic pitfalls include recognizing subtle T-cell proliferation and interpreting molecular abnormalities.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Madlen Jentzsch, Lara Bischof, Donata Backhaus, Dominic Brauer, Julia Schulz, Georg-Nikolaus Franke, Vladan Vucinic, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind
Summary: Allogeneic hematopoietic stem cell transplantation is a crucial treatment option for acute myeloid leukemia patients. The measurable residual disease status at transplantation, combined with the genetic risk at diagnosis, provides refined prognostic information.
Article
Hematology
Marius Bill, Madlen Jentzsch, Lara Bischof, Jessica Kohlschmidt, Juliane Grimm, Laura Katharina Schmalbrock, Donata Backhaus, Dominic Brauer, Karoline Goldmann, Georg -Nikolaus Franke, Vladan Vucinic, Dietger Niederwieser, Alice S. Mims, Uwe Platzbecker, Ann-Kathrin Eisfeld, Sebastian Schwind
Summary: Somatic mutations in IDH1 and IDH2 genes are common in AML. The presence of IDH mutations may not significantly impact the prognosis of AML patients consolidated by HSCT, but specific mutation locations (IDH1 R132, IDH2 R140, and IDH2 R172) and mutation dynamics do affect the risk of relapse. IDH2 R140 mutations behave more like clonal hematopoiesis-related aberrations, while IDH1 R132 and IDH2 R172 harbor AML disease-specific features.
Article
Biophysics
Donata Backhaus, Dominic Brauer, Rosmarie Pointner, Lara Bischof, Vladan Vucinic, Georg-Nikolaus Franke, Dietger Niederwieser, Uwe Platzbecker, Madlen Jentzsch, Sebastian Schwind
Summary: The impact of higher HCT-CI risk on NMA-HSCT outcomes in older AML patients is not significant, suggesting that age and comorbidities should not prevent the use of this treatment option.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Song-Yau Wang, Tanja Holzhey, Simone Heyn, Thomas Zehrfeld, Susann Fricke, Franz Albert Hoffmann, Cornelia Becker, Leanthe Braunert, Thomas Edelmann, Inessa Paulenz, Marcus Hitzschke, Franziska Flade, Andreas Schwarzer, Klaus Fenchel, Georg-Nikolaus Franke, Vladan Vucinic, Madlen Jentzsch, Sebastian Schwind, Saskia Hell, Donata Backhaus, Thoralf Lange, Dietger Niederwieser, Markus Scholz, Uwe Platzbecker, Wolfram Poenisch
Summary: Autologous stem cell transplantation (ASCT) is the standard treatment for younger patients with newly diagnosed multiple myeloma (MM). However, many eligible patients are excluded from transplant studies due to restrictive exclusion criteria. This retrospective analysis included 540 MM patients who received ASCT between 1996 and 2019.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Thomas Walter Georgi, Lars Kurch, Georg-Nikolaus Franke, Madlen Jentzsch, Sebastian Schwind, Carmen Perez-Fernandez, Naima Petermann, Maximilian Merz, Klaus Metzeler, Gudrun Borte, Sandra Hoffmann, Marco Herling, Timm Denecke, Regine Kluge, Osama Sabri, Uwe Platzbecker, Vladan Vucinic
Summary: Assessing the value of FDG-PET/CT in predicting patient outcomes after CAR-T cell therapy, it was found that PET-1 results were significantly associated with patient prognosis. Patients with CMR had better outcomes, while those without CMR had poorer outcomes.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Petra Buettner, Julia Boettner, Knut Krohn, Ronny Baber, Uwe Platzbecker, Michael Cross, Steffen Desch, Holger Thiele, Sabine Steiner, Dierk Scheinert, Klaus H. Metzeler, Daniela Branzan
Summary: In this pilot study, it was found that clonal hematopoiesis (CH)-associated mutations can be detected in both peripheral blood cells and tissues associated with atherosclerosis, suggesting a potential impact on disease physiology.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Madlen Jentzsch, Lara Bischof, Dominic Brauer, Donata Backhaus, Jule Ussmann, Georg-Nikolaus Franke, Vladan Vucinic, Uwe Platzbecker, Sebastian Schwind
Summary: The presence and allelic ratio of FLT3-ITD have been recognized as prognostic factors in acute myeloid leukemia (AML), but their impact on patient outcomes after allogeneic hematopoietic stem cell transplantation (HSCT) is not well understood. This study found that the FLT3-ITD allelic ratio did not significantly affect survival in patients undergoing HSCT, but highlighted the importance of pre-HSCT measurable residual disease (MRD) as a prognostic factor.
Letter
Oncology
A. S. Kubasch, P. Peterlin, T. Cluzeau, K. S. Goetze, K. Sockel, R. Teipel, M. Jentzsch, H. Attalah, M. Sebert, F. Chermat, S. Gloaguen, M. Puttrich, M. Cross, M. Schneider, S. Kayser, D. Schipp, A. Giagounidis, I. Tirado-Gonzalez, A. Descot, A. van de Loosdrecht, A. Weigert, K. H. Metzeler, P. Fenaux, H. Medyouf, U. Platzbecker, L. Ades
Meeting Abstract
Biophysics
L. Bischof, C. Rolfs, D. Backhaus, D. Brauer, L. Herrmann, J. Schulz, G. -N. Franke, V. Vucinic, M. Cross, U. Platzbecker, M. Jentzsch, S. Schwind
BONE MARROW TRANSPLANTATION
(2022)
Meeting Abstract
Biophysics
G. -N. Franke, V. Vucinic, B. Schetschorke, J. Classen, U. Platzbecker, W. Koehler
BONE MARROW TRANSPLANTATION
(2022)
Meeting Abstract
Oncology
S. Schwind, L. Herrmann, L. Bischof, D. Backhaus, D. Brauer, G. -N. Franke, V. Vucinic, U. Platzbecker, M. Jentzsch
ONCOLOGY RESEARCH AND TREATMENT
(2022)